ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 679

Patients with Psoriatic Arthritis and Oligoarthritic Subtype Report Higher Disease Burden Than Patients with a Polyarthritic Pattern – Data from the German Collaborative Arthritis Centres

Dörte Huscher1, Katinka Albrecht2, Sascha Bischoff2, Katja Thiele2, Frank Behrens3, Kathrin Fischer4, Ulrich von Hinüber5, Susanna Späthling-Mestekemper6, Siegfried Wassenberg7 and Angela Zink1, 1German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, 2German Rheumatism Research Centre, Berlin, Germany, 3CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, 4Praxis fuer Innere Medizin, Aerztehaus Schoenwalde, Greifswald, Germany, 5Practice-based rheumatologist, Hildesheim, Germany, 6Practice-based rheumatologist, München, Germany, 7Rheumaklinik, Themistocles Gluck hospital - Rheumazentrum Ratingen, Ratingen, Germany

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Disease Activity, observation, patient outcomes, psoriatic arthritis and treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriatic arthritis (PsA) divides into different subtypes, of which polyarthritis and spondylitis would be expected with the highest disease severity. We compared disease burden in PsA patients with oligo- and polyarthritic subtype in the national database of the German Collaborative Arthritis Centres.

Methods: We added a specific PsA module to the standard documentation of the national database of the German arthritis centres, containing data on the predominant PsA subtype (according to physicians’ decision), associated skin, joint and other musculoskeletal manifestations. In addition to the Dermatology Life Quality Index (DLQI 0-30), patients reported specific questions concerning PsA-related disease burden. Between 2007 and 2013, in total 707 patients were documented.

Results: PsA patterns comprised 41% oligoarthritis (OA), 46% polyarthritis (PA), 6.4% arthritis of the distal interphalangeal joints (ADIP) or exclusively axial PsA (aPsA) each, and 0.8% patients with dominant arthritis mutilans. Age was comparable between all groups; female proportion was highest in OA. Disease severity was assessed by the physician as highest in aPsA, disease activity as highest in PA and ADIP. Focussing on OA and PA, joint and axial involvement, dactylitis, osteoproliferations and comorbid conditions were more frequent in OA, while psoriasis severity was higher in PA. OA was less often treated with biologics, while use of NSAIDs and opioids was higher than in PA. Patient reported outcomes (PRO) were worse in OA with regard to joint and skin conditions, pain and fatigue. When matching OA and PA by disease duration and gender (n=222 pairs with similar age, data not shown), disparities in physician’s disease assessment and PROs as well as treatment differences persisted. In addition to the higher comorbid burden, current regular smoking was more frequently seen in OA patients (23% vs. 16%).

Conclusion: Despite comparable disease activity and severity measured by clinical examination PsA patients with oligoarthritic compared to polyarthritic subtype show a higher patient reported disease burden, which has to be further examined. Optimising therapy, incorporating comorbidities and councelling the patient against smoking may bear potential to further improve quality of life in PsA-OA.


Disclosure: D. Huscher, None; K. Albrecht, None; S. Bischoff, None; K. Thiele, None; F. Behrens, None; K. Fischer, None; U. von Hinüber, None; S. Späthling-Mestekemper, None; S. Wassenberg, None; A. Zink, AbbVie, Celltrion, Hospira, Bristol-Myers Squibb, MSD Sharp&Dohme, Pfizer, Roche, and UCB., 2,BMS, Merck-Sharp & Dohme, Pfizer, Roche, UCB., 9.

To cite this abstract in AMA style:

Huscher D, Albrecht K, Bischoff S, Thiele K, Behrens F, Fischer K, von Hinüber U, Späthling-Mestekemper S, Wassenberg S, Zink A. Patients with Psoriatic Arthritis and Oligoarthritic Subtype Report Higher Disease Burden Than Patients with a Polyarthritic Pattern – Data from the German Collaborative Arthritis Centres [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/patients-with-psoriatic-arthritis-and-oligoarthritic-subtype-report-higher-disease-burden-than-patients-with-a-polyarthritic-pattern-data-from-the-german-collaborative-arthritis-centres/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patients-with-psoriatic-arthritis-and-oligoarthritic-subtype-report-higher-disease-burden-than-patients-with-a-polyarthritic-pattern-data-from-the-german-collaborative-arthritis-centres/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology